BCL-XL is an actionable target for treatment of malignant pleural mesothelioma

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Malignant pleural mesothelioma (MPM) has poor survival rates with limited treatment options.
• Current standard-of-care involves Cisplatin and Pemetrexed chemotherapy.
• There have been no new approved MPM treatments in over a decade.

Purpose of the Study:

• To investigate the efficacy of BH3-mimetic drugs targeting BCL-2 family proteins in MPM.
• To identify dominant pro-survival proteins in MPM cells.
• To evaluate combination therapies involving BH3-mimetics and standard chemotherapy.

Main Methods:

• Screening of BH3-mimetic drugs against MPM cell lines.
• Assessing synergistic cell killing with co-targeting of pro-survival proteins.
• Evaluating BCL-XL inhibition combined with Cisplatin in vitro and in vivo.
• Investigating the role of MCL-1 through genetic ablation.

Main Results:

• BCL-XL was identified as the dominant pro-survival protein in MPM cell lines.
• Co-targeting MCL-1 with BCL-XL inhibitors resulted in synergistic cell killing.
• BCL-XL inhibition showed efficacy comparable to Cisplatin in vivo.
• Combination therapy enhanced tumor growth control and prolonged survival in vivo.

Conclusions:

• BH3-mimetic drugs targeting BCL-XL represent a promising therapeutic strategy for MPM.
• Combination of BCL-XL inhibition with Cisplatin warrants clinical investigation.
• Targeting BCL-XL, potentially with MCL-1 co-inhibition, offers a rationale for novel MPM treatments.